News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure at the threshold of a breakthrough in the treatment of inflammatory and fibrotic diseases. The focus on the most breakthrough therapy and the OATD-01 and OATD-02 clinical trials results in a reduction of programs in the discovery phase from five to three
15 October 2024
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors
15 October 2024
Invitation to investor meeting 16th October 2024, 10:00 am (CET)
14 October 2024
Molecure has released its financial report for the first half of 2024. The company continues to develop innovative therapies in the fight against oncological and inflammatory-fibrotic diseases
27 September 2024
Invitation to investor meeting 1st October 2024, 2:00 pm (CET)
23 September 2024
Dr Piotr Iwanowski appointed as Chief Medical Officer and Board Member of Molecure
1 August 2024